AI-generated summary
The authors report a randomized, double-masked study of the LacryStim intense pulsed light device in 25 patients with meibomian gland dysfunction, with one eye treated and the other sham-treated. They found no significant difference between treated and sham eyes in meibum quality or expressibility at six months, though both groups showed a trend toward better expressibility and subjective symptom scores improved. No device-related adverse events were observed.
- Participants
- 25
- Who or what was studied
- Patients with meibomian gland dysfunction (25 patients, 50 eyes)
- Limits stated in the abstract
- The abstract describes a small sample of 25 patients and the authors note that an intra-individual design may complicate analysis of each eye.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on link.springer.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Energy density (fluence)
- 8 J/cm2, 1 J/cm2
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Sham, Primary outcome. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.